TPEx-Listed HanchorBio Advances Global Impact of HCB101 Immunotherapy
TAIPEI, SHANGHAI and SAN FRANCISCO, July 16, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827.TWO), a pioneer of immunotherapy biologics, is announcing its official listing on the Taipei Exchange (TPEx) Emerging Stock Board under the ticker symbol 7827.TWO and the name Hanchor-KY
This article is featured on another website.
Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
Mytrelle at Meeting on the Mesa
Myrtelle Announces Presentation of Encouraging Interim Results from its Phase 1/2 Gene Therapy Trial for Canavan Disease at the 2025 Cell & Gene Meeting on the Mesa
Mytrelle at Meeting on the Mesa
Myrtelle Announces Presentation of Encouraging Interim Results from its Phase 1/2 Gene Therapy Trial for Canavan Disease at the 2025 Cell & Gene Meeting on the Mesa